FIELD: pharmaceutics.
SUBSTANCE: present invention relates to substituted pyridine compounds that are modulators of cystic fibrosis transmembrane conductance regulator protein (hereinafter – CFTR), suitable for the treatment of diseases and conditions mediated and modulated by CFTR. The compound of (5-{3-amino-5-[4-(trifluoromethoxy))benzene-1-sulfonyl]pyridine-2-yl}-1,3,4-oxadiazol-2-yl)methanol or its pharmaceutically acceptable salt is specifically described, as well as a pharmaceutical composition for the treatment of cystic fibrosis containing therapeutically effective amount of the compound or its pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier.
EFFECT: technical result is producing pyridines substituted with heteroaryl.
4 cl, 7 tbl, 67 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZINE DERIVATIVES USED AS ATR KINASE INHIBITORS | 2009 |
|
RU2604066C2 |
| NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITING NAMPT | 2011 |
|
RU2616612C2 |
| COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | 2015 |
|
RU2767460C2 |
| COMPOUND BASED ON DIHYDRONAPTHYRIDINONE, METHOD OF ITS OBTAINING, AND ITS USE IN MEDICINE | 2021 |
|
RU2809869C1 |
| MODULATORS OF ATP-BINDING TRANSPORTERS | 2010 |
|
RU2552353C2 |
| SUBSTITUTED TRICYCLIC COMPOUNDS AND METHOD OF APPLICATION | 2016 |
|
RU2744766C2 |
| PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS | 2019 |
|
RU2806758C2 |
| NEW COMPOUNDS AND COMPOSITIONS FOR NAMPT INHIBITION | 2011 |
|
RU2617988C2 |
| MODULATORS OF ATP-BINDING CARTRIDGE TRANSPORTERS | 2005 |
|
RU2528046C2 |
| INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | 2007 |
|
RU2474576C2 |
